Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REC-4881 in familial adenomatous polyposis
NL-OMON61359Phase 2Not yet recruiting
- Sponsor
- Recursion Pharmaceuticals
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of TAK-733 in Colonic Adenomatous Polyposis (3 arms), sponsored by Recursion Pharmaceuticals. Primary endpoints: Plasma pharmacokinetic parameters, Safety and tolerability and 3 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
TAK-733
03
Conditions
Colonic Adenomatous Polyposis
Beyond the preview
Go deeper on NL-OMON61359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61359.